Showing results (11-20 of 1,409) with videos related to

Sort By:
Pageof 141
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2021
Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR MutationsJoshua K Sabari, John V Heymach, Beth Sandy
Molecular Diagnosis & Therapy|April 21, 2012
Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlookJoaquin Mateo, John V Heymach, Amado J Zurita
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|December 13, 2019
β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-BlockersMonique B Nilsson, Xiuning Le, John V Heymach
Current Opinion in Oncology|March 15, 2016
MYB-fusions and other potential actionable targets in adenoid cystic carcinomaRenata Ferrarotto, John V Heymach, Bonnie S Glisson
Current Oncology Reports|March 22, 2012
Circulating biomarkers in advanced renal cell carcinoma: clinical applicationsMaria Hernandez-Yanez, John V Heymach, Amado J Zurita
Therapeutic Advances in Medical Oncology|March 1, 2021
Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancerLingzhi Hong, Jianjun Zhang, John V Heymach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancerJohn V Heymach, Monique Nilsson, George Blumenschein, et al.
Cancer Cell|August 13, 2021
ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLCXiuning Le, Monique B Nilsson, Jacqulyne P Robichaux, et al.
Chinese Journal of Cancer|July 3, 2015
Predictive biomarkers in precision medicine and drug development against lung cancerBingliang Fang, Reza J Mehran, John V Heymach, et al.
Clinical Lung Cancer|April 18, 2020
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial ReportPierre-Olivier Gaudreau, J Jack Lee, John V Heymach, et al.
Pageof 141